Atrium Therapeutics, Inc. Common Stock
$ 14.54
3.71%
15 Apr - close price
- Market Cap 217,520,000 USD
- Current Price $ 14.54
- High / Low $ 14.60 / 13.91
- Stock P/E N/A
- Book Value -4.04
- EPS -4.48
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -3.99 %
- ROE -0.44 %
- 52 Week High 73.06
- 52 Week Low 11.95
About
Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
Analyst Target Price
$25.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-10 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-09 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -1.59 | -1.27 | -1.21 | -0.9 | -0.8 | -0.65 | -0.65 | -0.79 | -0.79 | -0.71 | -0.66 | -0.74 |
| Estimated EPS | -1.24 | -1.14 | -0.9562 | -0.8803 | -0.7809 | -0.71 | -0.79 | -0.78 | -0.66 | -0.77 | -0.8 | -0.85 |
| Surprise | -0.35 | -0.13 | -0.2538 | -0.0197 | -0.0191 | 0.06 | 0.14 | -0.01 | -0.13 | 0.06 | 0.14 | 0.11 |
| Surprise Percentage | -28.2258% | -11.4035% | -26.5426% | -2.2379% | -2.4459% | 8.4507% | 17.7215% | -1.2821% | -19.697% | 7.7922% | 17.5% | 12.9412% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNA
2026-03-27 02:38:50
Linklaters advised a global underwriting syndicate on an USD 11 billion SEC-registered bond issuance by Novartis. The proceeds will be used for general corporate purposes and to repay a bridge loan that financed Novartis' USD 12 billion acquisition of Avidity Biosciences. The international Linklaters team was led by Marco Carbonare, Kevin Roy, and Danelle Le Cren.
2026-03-24 11:09:41
CAMP4 Therapeutics (Nasdaq: CAMP) has appointed Michael MacLean, a veteran biotech CFO with over 35 years of experience, to its Board of Directors. This strategic move coincides with the company advancing its CMP-002 program for SYNGAP1-related disorder towards a planned first-in-human Phase 1/2 clinical trial. MacLean's extensive background includes leadership roles at Avidity Biosciences, Akcea Therapeutics, PureTech Health, and Biogen, bringing valuable financial and operational expertise to CAMP4 during this critical growth phase.
2026-03-19 14:11:52
Atrium Therapeutics, a spin-off from Avidity Biosciences following its acquisition by Novartis, is pioneering precision RNA therapeutics for rare, genetic cardiomyopathies. The company, launched with $270 million in funding and a Novartis-validated delivery platform, aims to develop treatments that target the underlying cause of these severe heart conditions. Atrium plans to file INDs for its lead assets in late 2026 and 2027, with the potential to expand its reach beyond rare diseases to broader cardiomyopathy patient populations.
2026-03-11 22:08:29
This article announces an SEC filing by Avidity Biosciences, Inc. (RNAM) of Form 15, which is a certification and notice of termination of registration under Section 12(g) or suspension of duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing was signed by Jaime Huertas, Secretary, on March 9, 2026. The company is headquartered in San Diego, California, and has common stock with a par value of $0.0001 per share.
2026-03-09 11:52:10
Atrium Therapeutics, a new RNA company, launched in February with $270 million in funding as a spinoff following Novartis' $12 billion acquisition of Avidity Biosciences. Atrium will focus on developing RNA therapeutics for rare muscle diseases, particularly in the precision cardiology space, leveraging Avidity's antibody-oligonucleotide conjugate (AOC) platform. The company plans to submit Investigational New Drug applications for two lead candidates, ATR 1072 and ATR 1086, later this year and in 2027, respectively, and retained Avidity's former CEO, Sarah Boyce, as chair of its board.
2026-03-09 10:52:06
This page provides access to Avidity Biosciences's (Ticker: RNAM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores from Rhea-AI, and end-of-day stock performance data to offer insights into market reactions. The resource is designed for investors and regulatory compliance professionals to navigate critical disclosures and financial reporting.
